Want to see DTIL full AI Analyst Report?
DTIL Stock Chart & Stats
$7.88
-$0.10(-2.09%)
At close: 4:00 PM EST
$7.88
-$0.10(-2.09%)
Day’s Range― - ―
52-Week Range$3.53 - $9.62
Previous CloseN/A
Volume55.33K
Average Volume (3M)562.85K
Market Cap
$203.06M
Enterprise Value$62.77
Total Cash (Recent Filing)$101.18M
Total Debt (Recent Filing)$28.47M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Aug 06, 2026EPS Estimate
-0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.66
Shares Outstanding25,802,246
10 Day Avg. Volume641,367
30 Day Avg. Volume562,845
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.58
Price to Sales (P/S)1.56
P/FCF Ratio-0.81
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$33.00Price Target Upside318.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.81
Revenue Forecast (FY)$18.59M
Bulls Say, Bears Say
Bulls Say
Clinical Evidence Of CccDNA EliminationDemonstrated biopsy evidence that PBGENE-HBV reduces and inactivates cccDNA provides durable validation of Precision’s ARCUS platform in a high‑unmet-need indication. This mechanistic proof materially strengthens clinical differentiation, partnership appeal, and long-term regulatory and commercial potential.
Extended Term Loan Maturity To 2029Pushing the term loan maturity to late 2029 materially lowers near-term refinancing pressure and extends runway for clinical programs. This structural capital relief enhances the firm’s ability to prioritize R&D execution and data generation without immediate debt-driven liquidity constraints.
Manageable Leverage And Positive EquityA more moderate capital structure versus prior years and positive equity create a firmer financial base for a clinical‑stage biotech. Manageable leverage supports continued investment in programs and reduces bankruptcy risk, improving capacity to absorb R&D shocks while pursuing partnerships.
Bears Say
Persistent Negative Cash FlowSustained negative operating and free cash flow indicates ongoing cash burn and dependency on external financing. Over the medium term this raises dilution or refinancing risk, forces prioritization of programs, and constrains ability to scale activities absent durable positive cash generation.
Unstable Revenue And ProfitabilityVolatile revenue and a swing back to sizable operating and net losses reflect inconsistent commercial traction and program timing risk. This unstable earnings trajectory undermines internal funding capacity and complicates multi‑year planning, increasing reliance on capital markets or partners.
Revenue Dependent On Collaborations, No Product SalesA business model driven by milestone, licensing, and service income produces lumpy, milestone‑dependent cash flows with limited recurring revenue. Without commercial products, sustainable, predictable revenue is distant, heightening execution and partner‑dependency risk for long-term financial stability.
Precision BioSciences News
DTIL FAQ
What was Precision Biosciences’s price range in the past 12 months?
Precision Biosciences lowest stock price was $3.53 and its highest was $9.62 in the past 12 months.
What is Precision Biosciences’s market cap?
Precision Biosciences’s market cap is $203.06M.
When is Precision Biosciences’s upcoming earnings report date?
Precision Biosciences’s upcoming earnings report date is Aug 06, 2026 which is in 17 days.
How were Precision Biosciences’s earnings last quarter?
Precision Biosciences released its earnings results on May 05, 2026. The company reported -$0.75 earnings per share for the quarter, missing the consensus estimate of -$0.655 by -$0.095.
Is Precision Biosciences overvalued?
According to Wall Street analysts Precision Biosciences’s price is currently Undervalued.
Does Precision Biosciences pay dividends?
Precision Biosciences does not currently pay dividends.
What is Precision Biosciences’s EPS estimate?
Precision Biosciences’s EPS estimate is -0.79.
How many shares outstanding does Precision Biosciences have?
Precision Biosciences has 25,802,246 shares outstanding.
What happened to Precision Biosciences’s price movement after its last earnings report?
Precision Biosciences reported an EPS of -$0.75 in its last earnings report, missing expectations of -$0.655. Following the earnings report the stock price went down -2.359%.
Which hedge fund is a major shareholder of Precision Biosciences?
Currently, no hedge funds are holding shares in DTIL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Precision BioSciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.00 (318.78% Upside)
$33.00 (318.78% Upside)
Blogger Sentiment
Bullish
DTIL Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 207.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 6.7%
Last 30 Days ▲ 6.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
69.61%
12-Months-Change
Fundamentals
Return on Equity
-81.24%
Trailing 12-Months
Asset Growth
15.66%
Trailing 12-Months
Company Description
Precision Biosciences
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases. The company's portfolio also encompasses Ex vivo Allogeneic CAR T Immunotherapy, an innovative approach where specific immune cells, known as T-cells, are genetically modified outside the body to precisely identify and eliminate cancer cells. Among its prominent therapeutic candidates are: PBCAR0191, currently undergoing Phase 1/2a clinical trials for adult patients battling relapsed/refractory (R/R) non-Hodgkin lymphoma or R/R B-cell precursor acute lymphoblastic leukemia (B-ALL). PBCAR19B, an anti-CD19 CAR T candidate leveraging a "stealth cell" platform through a single-step gene edit, engineered to reduce the likelihood of chromosomal abnormalities. PBCAR269A, an investigational allogeneic CAR T immunotherapy formulated to target BCMA, intended for the treatment of R/R multiple myeloma. Precision BioSciences has strategically formed several collaborative alliances. These include an agreement with Les Laboratoires Servier for the development and commercialization of allogeneic chimeric antigen receptor T-cell therapies, aimed at various antigen targets, including hematological cancers beyond CD19, and solid tumors. The company is also partnering with Tiziana Life Sciences to assess foralumab, a fully human anti-CD3 monoclonal antibody, for its utility as a lymphodepleting agent in potential cancer treatments. Furthermore, a collaboration with iECURE, Inc. focuses on advancing ARCUS-based gene editing therapies. Established in 2006, Precision BioSciences, Inc. maintains its corporate headquarters in Durham, North Carolina.
DTIL Stock 12 Month Forecast
Average Price Target
$33.00
▲(318.78% Upside)
Technical Analysis
Ownership Overview
2.98% Insiders
5.41% Mutual Funds
0.17% Other Institutional Investors
82.27% Public Companies and
Individual Investors